Intravitreal interferon α-2b for the treatment of neovascular age-related macular degeneration: A pilot study

Canadian Journal of Ophthalmology

Volumn 32, Issue 3, 1997, Pages 185-188

  Kertes, Peter J ^b   Britton Jr , William A ^a,c   Leonard, Brian C ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

age related macular degeneration; choroidal neovascularization; drug toxicity; interferon

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; CASE REPORT; FOLLOW UP; HUMAN; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

EID: 0030976891     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Canadian National Institute for the Blind annual report. Toronto: Canadian National Institute for the Blind, 1990.
2. Leibowitz H, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph. An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24(suppl):335-610.
3. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-31.
5. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516-21.
6. Sidsky YA, Borden EL. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
7. Gillies MC, Su T. Reduction of in vitro retinal microvascular permeability by interferon alpha 2B [abstract]. Invest Ophthalmol Vis Sci 1994;35(suppl):2087.
8. Fung WE. Interferon alpha 2A for the treatment of age-related macular degeneration. Am J Ophthalmol 1991;112: 349-50.
9. Chan CK, Kempin SJ, Noble SK, Palmer GA. The treatment of choroidal neovascular membranes by alpha interferon: an efficacy and toxicity study. Ophthalmology 1994; 101:289-300.
10. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993;100:9-14.
11. Kertes PJ, Britton WA Jr, Addison DJ, Munro SM, Marshall DH, Leonard BC. Toxicity of intravitreal interferon α-2b in the rabbit. Can J Ophthalmol 1995;30:355-9.
12. Karaçorlu MA, Peyman GA, Cruz S, Soike KF. Lack of toxicity of intravitreally administered interferon α-2A. Ophthalmic Surg 1992;23:833-5.
13. Peyman GA, Schulman JA. Intravitreal surgery: principles and practice. Norwalk (CT): Appleton-Century-Crofts, 1986:407-56.